Premium
l ‐3,4‐dihydroxyphenylalanine ( l ‐DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha‐synuclein mouse models of Parkinson's disease
Author(s) -
Billings Jessica L.,
Gordon Sarah L.,
Rawling Tristan,
Doble Philip A.,
Bush Ashley I.,
Adlard Paul A.,
Finkelstein David I.,
Hare Dominic J.
Publication year - 2019
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/jnc.14676
Subject(s) - neurodegeneration , substantia nigra , neuroprotection , pars compacta , oxidative stress , dopamine , clioquinol , dopaminergic , chemistry , alpha synuclein , parkinson's disease , pharmacology , biochemistry , neuroscience , biology , medicine , disease
Abstract Treatment with the dopamine ( DA ) precursor l ‐3,4‐dihydroxyphenylalanine ( l ‐ DOPA ) provides symptomatic relief arising from DA denervation in Parkinson's disease. Mounting evidence that DA autooxidation to neurotoxic quinones is involved in Parkinson's disease pathogenesis has raised concern about potentiation of oxidative stress by l ‐ DOPA . The rate of DA quinone formation increases in the presence of excess redox‐active iron (Fe), which is a pathological hallmark of Parkinson's disease. Conversely, l ‐ DOPA has pH ‐dependent Fe‐chelating properties, and may act to ‘redox silence’ Fe and partially allay DA autoxidation. We examined the effects of l ‐ DOPA in three murine models of parkinsonian neurodegeneration: early‐life Fe overexposure in wild‐type mice, transgenic human (h)A53T mutant α‐synuclein (α‐syn) over‐expression, and a combined ‘multi‐hit’ model of Fe‐overload in hA 53T mice. We found that l ‐ DOPA was neuroprotective and prevented age‐related Fe accumulation in the substantia nigra pars compacta ( SN c), similar to the mild‐affinity Fe chelator clioquinol. Chronic l ‐ DOPA treatment showed no evidence of increased oxidative stress in wild‐type midbrain and normalized motor performance, when excess Fe was present. Similarly, l ‐ DOPA also did not exacerbate protein oxidation levels in hA 53T mice, with or without excess nigral Fe, and showed evidence of neuroprotection. The effects of l ‐ DOPA in Fe‐fed hA 53T mice were somewhat muted, suggesting that Fe‐chelation alone is insufficient to attenuate neuron loss in an animal model also recapitulating altered DA metabolism. In summary, we found no evidence in any of our model systems that l ‐ DOPA treatment accentuated neurodegeneration, suggesting DA replacement therapy does not contribute to oxidative stress in the Parkinson's disease brain.